Literature DB >> 27260496

Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity.

C-B Yeh1, S-J Weng2, K-W Chang3, J Y-H Chan4, S-M Huang5, T-H Chu2, N-K Wei2, H-S Ma2, J-T Cheng2, K-H Ma2, T-H Chen6,7, J-F Shyu8.   

Abstract

Calcitonin may relieve pain by modulating central serotonin activity. Calcitonin partly reversed the hypersensitivity to pain induced by ovariectomy. This suggests that the anti-nociceptive effects of calcitonin in the treatment of osteoporosis may be mediated by alterations in neural serotonin transporter (SERT) activity.
INTRODUCTION: This study used a rat model of osteoporosis to evaluate the role of the cerebral serotonin system in the anti-nociceptive effect of calcitonin, a drug used to treat post-menopausal osteoporosis.
METHODS: Osteoporosis was induced in rats by ovariectomy (OVX). Rats were then randomized to the following four groups: sham operation, OVX, OVX plus calcitonin, or OVX plus alendronate.
RESULTS: OVX led to alterations in bone micro-architecture; alendronate strongly reversed this effect, and calcitonin moderately reversed this effect. OVX increased hyperalgesia (determined as the time for hind paw withdrawal from a heat source); calcitonin reduced this effect, but alendronate had no effect. OVX increased the expression of c-Fos (a neuronal marker of pain) in the thalamus; calcitonin strongly reversed this effect, and alendronate moderately reversed this effect. OVX also reduced SERT but increased 5-HT1A receptor expression and activity; calcitonin aggravated this effect, but alendronate had no effect on recovery of SERT/5-HT1A activity and expression.
CONCLUSIONS: Our study of a rat model of osteoporosis suggests that OVX-induced enhancement of the serotonergic system may protect against hyperalgesia. However, the anti-nociceptive effects of calcitonin in osteoporosis may be mediated by decreased neural SERT activity and increased activation of 5-HT1 receptors in the thalamus.

Entities:  

Keywords:  Alendronate; Calcitonin; Hyperalgesia; Osteoporosis; Serotonin transporter

Mesh:

Substances:

Year:  2016        PMID: 27260496     DOI: 10.1007/s00198-016-3652-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  43 in total

Review 1.  Possible mechanisms of the analgesic action of calcitonin.

Authors:  M Azria
Journal:  Bone       Date:  2002-05       Impact factor: 4.398

2.  Calcitonin in painful diabetic neuropathy.

Authors:  A Quatraro; A Minei; N De Rosa; D Giugliano
Journal:  Lancet       Date:  1992-03-21       Impact factor: 79.321

3.  Analgesic mechanism of calcitonin.

Authors:  M Yoshimura
Journal:  J Bone Miner Metab       Date:  2000       Impact factor: 2.626

Review 4.  Analgesic effect of calcitonin in osteoporosis.

Authors:  C Gennari
Journal:  Bone       Date:  2002-05       Impact factor: 4.398

5.  [The effects of the carbocalcitonin + arginine-lysine-lactose combination in senile involutional osteoporosis].

Authors:  G Abate; F Taormina; C Brillante; L Fraccalaglio
Journal:  Minerva Med       Date:  1994-05       Impact factor: 4.806

Review 6.  Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT.

Authors:  Laurent Descarries; Mustaph Riad
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

7.  Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity.

Authors:  V Sibilia; F Pagani; N Lattuada; D Rapetti; F Guidobono; C Netti
Journal:  Brain Res       Date:  2000-01-31       Impact factor: 3.252

8.  Calcitonin, an enigmatic hormone: does it have a function?

Authors:  P F Hirsch; G E Lester; R V Talmage
Journal:  J Musculoskelet Neuronal Interact       Date:  2001-06       Impact factor: 2.041

Review 9.  Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality.

Authors:  Morten A Karsdal; Kim Henriksen; Michel Arnold; Claus Christiansen
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

10.  Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery.

Authors:  Yogendra P Kharode; Michael C Sharp; Peter V N Bodine
Journal:  Methods Mol Biol       Date:  2008
View more
  5 in total

Review 1.  Pathomechanisms and management of osteoporotic pain with no traumatic evidence.

Authors:  Sumihisa Orita; Kazuhide Inage; Miyako Suzuki; Kazuki Fujimoto; Kazuyo Yamauchi; Junichi Nakamura; Yusuke Matsuura; Takeo Furuya; Masao Koda; Kazuhisa Takahashi; Seiji Ohtori
Journal:  Spine Surg Relat Res       Date:  2017-12-20

Review 2.  Calcitonin: A useful old friend.

Authors:  Akash Srinivasan; Felyx K Wong; Dimitrios Karponis
Journal:  J Musculoskelet Neuronal Interact       Date:  2020-12-01       Impact factor: 2.041

Review 3.  Beyond CGRP: The calcitonin peptide family as targets for migraine and pain.

Authors:  Tayla A Rees; Erica R Hendrikse; Debbie L Hay; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2021-07-27       Impact factor: 9.473

Review 4.  Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression.

Authors:  Akitoshi Ito; Megumu Yoshimura
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

Review 5.  [Calcitonin as an analgesic agent: review of mechanisms of action and clinical applications].

Authors:  Javad Yazdani; Reza Khorshidi Khiavi; Mohammad Ali Ghavimi; Ali Mortazavi; Elahe Jabbari Hagh; Farzin Ahmadpour
Journal:  Braz J Anesthesiol       Date:  2019-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.